Literature DB >> 29178447

Phenotype and genotype analysis of a French cohort of 119 patients with CHARGE syndrome.

Marine Legendre1,2, Véronique Abadie3,4, Tania Attié-Bitach5,6, Nicole Philip7, Tiffany Busa7, Dominique Bonneau8, Estelle Colin8, Hélène Dollfus9, Didier Lacombe10, Annick Toutain11, Sophie Blesson11, Sophie Julia12, Dominique Martin-Coignard13, David Geneviève14, Bruno Leheup15, Sylvie Odent16, Pierre-Simon Jouk17, Sandra Mercier18, Laurence Faivre19, Catherine Vincent-Delorme20, Christine Francannet21, Sophie Naudion10, Michèle Mathieu-Dramard22, Marie-Ange Delrue10, Alice Goldenberg23, Delphine Héron24, Philippe Parent25, Renaud Touraine26, Valérie Layet27, Damien Sanlaville28, Chloé Quélin16, Sébastien Moutton10, Mélanie Fradin16, Aurélia Jacquette24, Sabine Sigaudy7, Lucile Pinson14, Pierre Sarda14, Anne-Marie Guerrot23, Massimiliano Rossi28, Alice Masurel-Paulet19, Salima El Chehadeh19, Xavier Piguel29, Montserrat Rodriguez-Ballesteros1, Stéphanie Ragot30,31, Stanislas Lyonnet5,6, Frédéric Bilan1,2, Brigitte Gilbert-Dussardier1,2.   

Abstract

CHARGE syndrome (CS) is a genetic disorder whose first description included Coloboma, Heart disease, Atresia of choanae, Retarded growth and development, Genital hypoplasia, and Ear anomalies and deafness, most often caused by a genetic mutation in the CHD7 gene. Two features were then added: semicircular canal anomalies and arhinencephaly/olfactory bulb agenesis, with classification of typical, partial, or atypical forms on the basis of major and minor clinical criteria. The detection rate of a pathogenic variant in the CHD7 gene varies from 67% to 90%. To try to have an overview of this heterogenous clinical condition and specify a genotype-phenotype relation, we conducted a national study of phenotype and genotype in 119 patients with CS. Selected clinical diagnostic criteria were from Verloes (2005), updated by Blake & Prasad (). Besides obtaining a detailed clinical description, when possible, patients underwent a full ophthalmologic examination, audiometry, temporal bone CT scan, gonadotropin analysis, and olfactory-bulb MRI. All patients underwent CHD7 sequencing and MLPA analysis. We found a pathogenic CHD7 variant in 83% of typical CS cases and 58% of atypical cases. Pathogenic variants in the CHD7 gene were classified by the expected impact on the protein. In all, 90% of patients had a typical form of CS and 10% an atypical form. The most frequent features were deafness/semicircular canal hypoplasia (94%), pituitary defect/hypogonadism (89%), external ear anomalies (87%), square-shaped face (81%), and arhinencephaly/anosmia (80%). Coloboma (73%), heart defects (65%), and choanal atresia (43%) were less frequent.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHARGE syndrome; CHD7 gene; genotype; phenotype

Mesh:

Substances:

Year:  2017        PMID: 29178447     DOI: 10.1002/ajmg.c.31591

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  18 in total

1.  A functional assay to study the pathogenicity of CHD7 protein variants encountered in CHARGE syndrome patients.

Authors:  Gara Samara Brajadenta; Frédéric Bilan; Brigitte Gilbert-Dussardier; Alain Kitzis; Vincent Thoreau
Journal:  Eur J Hum Genet       Date:  2019-07-09       Impact factor: 4.246

2.  The core SWI/SNF catalytic subunit Brg1 regulates nephron progenitor cell proliferation and differentiation.

Authors:  Jeannine M Basta; Ajeet P Singh; Lynn Robbins; Lisa Stout; Michelle Pherson; Michael Rauchman
Journal:  Dev Biol       Date:  2020-06-03       Impact factor: 3.582

Review 3.  Genetics of syndromic ocular coloboma: CHARGE and COACH syndromes.

Authors:  Aman George; Tiziana Cogliati; Brian P Brooks
Journal:  Exp Eye Res       Date:  2020-02-04       Impact factor: 3.467

Review 4.  An update on the genetics of ocular coloboma.

Authors:  Aisha S ALSomiry; Cheryl Y Gregory-Evans; Kevin Gregory-Evans
Journal:  Hum Genet       Date:  2019-05-09       Impact factor: 4.132

5.  Should autism spectrum disorder be considered part of CHARGE syndrome? A cross-sectional study of 46 patients.

Authors:  Véronique Abadie; Priscilla Hamiaux; Stéphanie Ragot; Marine Legendre; Gaelle Malecot; Alexia Burtin; Tania Attie-Bitach; Stanislas Lyonnet; Frédéric Bilan; Brigitte Gilbert-Dussardier; Laurence Vaivre-Douret
Journal:  Orphanet J Rare Dis       Date:  2020-06-03       Impact factor: 4.123

6.  High frequency of CHD7 mutations in congenital hypogonadotropic hypogonadism.

Authors:  Catarina Inês Gonçalves; Filipa Marina Patriarca; José Maria Aragüés; Davide Carvalho; Fernando Fonseca; Sofia Martins; Olinda Marques; Bernardo Dias Pereira; José Martinez-de-Oliveira; Manuel Carlos Lemos
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

7.  An analysis of body proportions in children with CHARGE syndrome using photogrammetric anthropometry.

Authors:  Bas Penders; Dieuwerke R Dijk; Gianni Bocca; Luc J I Zimmermann; Conny M A van Ravenswaaij-Arts; Willem-Jan M Gerver
Journal:  Am J Med Genet A       Date:  2019-05-27       Impact factor: 2.802

8.  CHD7 promotes neural progenitor differentiation in embryonic stem cells via altered chromatin accessibility and nascent gene expression.

Authors:  Hui Yao; Douglas F Hannum; Yiwen Zhai; Sophie F Hill; Ricardo D 'Oliveira Albanus; Wenjia Lou; Jennifer M Skidmore; Gilson Sanchez; Alina Saiakhova; Stephanie L Bielas; Peter Scacheri; Mats Ljungman; Stephen C J Parker; Donna M Martin
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

9.  Neuroimaging in Kabuki syndrome and another KMT2D-related disorder.

Authors:  Rachel T Stadelmaier; Margaret A Kenna; Devon Barrett; Thomas E Mullen; Olaf Bodamer; Pankaj B Agrawal; Caroline D Robson; Monica H Wojcik
Journal:  Am J Med Genet A       Date:  2021-08-09       Impact factor: 2.802

Review 10.  Congenital heart defects in CHARGE: The molecular role of CHD7 and effects on cardiac phenotype and clinical outcomes.

Authors:  Joshua K Meisner; Donna M Martin
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-12-13       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.